Statement From Naike Ledan, Health GAP Director of International Policy & Advocacy, on Colombia's Historic Compulsory License for Dolutegravir
February 08, 2024
February 08, 2024
BROOKLYN, New York, Feb. 8 -- Health Global Access Project issued the following statement on Feb. 6, 2024, by Naike Ledan, director of international policy and advocacy, on Colombia's historic compulsory license for dolutegravir:
* * *
"Dolutegravir (DTG) is a lifesaving HIV treatment that can improve and extend the lives of people with HIV. DTG-based regimens are more effective and recommended by the World Health Organization as the preferred HIV treatment option . . .
* * *
"Dolutegravir (DTG) is a lifesaving HIV treatment that can improve and extend the lives of people with HIV. DTG-based regimens are more effective and recommended by the World Health Organization as the preferred HIV treatment option . . .